Identification of the Optimal Cut-Off Value of PSA for Assessing Severity of Disease in [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT Study in Prostate Cancer Patients after Radical Prostatectomy

Objective: The objective of this study was to identify the optimal cut-off value of prostate specific antigen (PSA) to assess the extent of the disease in [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT study in patients after radical prostatectomy. Materials and Methods: Retrospective analysis was p...

Full description

Bibliographic Details
Main Authors: Paulina Cegla, Marta Wojewódzka, Izabela Gorczewska, Wioletta Chalewska, Grażyna Łapińska, Paweł Ochman, Agata Sackiewicz, Marek Dedecjus
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Diagnostics
Subjects:
Online Access:https://www.mdpi.com/2075-4418/12/2/349
_version_ 1797481206163439616
author Paulina Cegla
Marta Wojewódzka
Izabela Gorczewska
Wioletta Chalewska
Grażyna Łapińska
Paweł Ochman
Agata Sackiewicz
Marek Dedecjus
author_facet Paulina Cegla
Marta Wojewódzka
Izabela Gorczewska
Wioletta Chalewska
Grażyna Łapińska
Paweł Ochman
Agata Sackiewicz
Marek Dedecjus
author_sort Paulina Cegla
collection DOAJ
description Objective: The objective of this study was to identify the optimal cut-off value of prostate specific antigen (PSA) to assess the extent of the disease in [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT study in patients after radical prostatectomy. Materials and Methods: Retrospective analysis was performed on a group of 215 patients who underwent a [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT examination because of suspected recurrence after radical prostatectomy. Patients were divided into four groups: 1, no active lesions suggesting recurrence (n = 92); 2, suspected isolated local recurrence (n = 19); 3, oligometastatic disease (n = 82); and 4, polymetastatic disease (n = 22). Results: In group 1, the mean PSA level was 0.962 ng/mL (median: 0.376; min: 0.004; max: 25 ng/mL); in group 2, it was 4.970 ng/mL (median 1.320; min: 0.003; max: 40.350 ng/mL); in group 3, it was 2.802 ng/mL (median: 1.270; min: 0.020; max: 59.670 ng/mL); and in group 4, it was 4.997 ng/mL (median: 3.795; min: 0.007; max 21.110 ng/mL). Statistically significant differences were shown in PSA levels when comparing groups 1 and 2 (<i>p</i> = 0.0025) and groups 3 and 4 (<i>p</i> = 0.0474). The PSA cut-off point for discriminating groups 1 and 2 was 0.831 (sensitivity: 0.684; specificity: 0.772; area under the curve (AUC): 0.775), and for groups 3 and 4, it was 2.51 (sensitivity: 0.682; specificity: 0.780; AUC: 0.720). Conclusions: Our preliminary data suggested that the PSA level has an essential influence on determining the extent of disease in a [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT study in patients after radical prostatectomy. Identification of the optimal cut-off values for the oligo- and polymetastatic diseases might be helpful in stratifying these patients.
first_indexed 2024-03-09T22:11:11Z
format Article
id doaj.art-3e469f50c7454ba3817664e0c27c0f74
institution Directory Open Access Journal
issn 2075-4418
language English
last_indexed 2024-03-09T22:11:11Z
publishDate 2022-01-01
publisher MDPI AG
record_format Article
series Diagnostics
spelling doaj.art-3e469f50c7454ba3817664e0c27c0f742023-11-23T19:30:34ZengMDPI AGDiagnostics2075-44182022-01-0112234910.3390/diagnostics12020349Identification of the Optimal Cut-Off Value of PSA for Assessing Severity of Disease in [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT Study in Prostate Cancer Patients after Radical ProstatectomyPaulina Cegla0Marta Wojewódzka1Izabela Gorczewska2Wioletta Chalewska3Grażyna Łapińska4Paweł Ochman5Agata Sackiewicz6Marek Dedecjus7Department of Endocrine Oncology and Nuclear Medicine, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, PolandDepartment of Endocrine Oncology and Nuclear Medicine, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, PolandDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 44-102 Gliwice, PolandDepartment of Endocrine Oncology and Nuclear Medicine, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, PolandDepartment of Endocrine Oncology and Nuclear Medicine, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, PolandDepartment of Endocrine Oncology and Nuclear Medicine, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, PolandDepartment of Endocrine Oncology and Nuclear Medicine, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, PolandDepartment of Endocrine Oncology and Nuclear Medicine, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, PolandObjective: The objective of this study was to identify the optimal cut-off value of prostate specific antigen (PSA) to assess the extent of the disease in [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT study in patients after radical prostatectomy. Materials and Methods: Retrospective analysis was performed on a group of 215 patients who underwent a [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT examination because of suspected recurrence after radical prostatectomy. Patients were divided into four groups: 1, no active lesions suggesting recurrence (n = 92); 2, suspected isolated local recurrence (n = 19); 3, oligometastatic disease (n = 82); and 4, polymetastatic disease (n = 22). Results: In group 1, the mean PSA level was 0.962 ng/mL (median: 0.376; min: 0.004; max: 25 ng/mL); in group 2, it was 4.970 ng/mL (median 1.320; min: 0.003; max: 40.350 ng/mL); in group 3, it was 2.802 ng/mL (median: 1.270; min: 0.020; max: 59.670 ng/mL); and in group 4, it was 4.997 ng/mL (median: 3.795; min: 0.007; max 21.110 ng/mL). Statistically significant differences were shown in PSA levels when comparing groups 1 and 2 (<i>p</i> = 0.0025) and groups 3 and 4 (<i>p</i> = 0.0474). The PSA cut-off point for discriminating groups 1 and 2 was 0.831 (sensitivity: 0.684; specificity: 0.772; area under the curve (AUC): 0.775), and for groups 3 and 4, it was 2.51 (sensitivity: 0.682; specificity: 0.780; AUC: 0.720). Conclusions: Our preliminary data suggested that the PSA level has an essential influence on determining the extent of disease in a [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT study in patients after radical prostatectomy. Identification of the optimal cut-off values for the oligo- and polymetastatic diseases might be helpful in stratifying these patients.https://www.mdpi.com/2075-4418/12/2/349positron emission tomography/computed tomographyprostate-specific membrane antigenprostate cancer
spellingShingle Paulina Cegla
Marta Wojewódzka
Izabela Gorczewska
Wioletta Chalewska
Grażyna Łapińska
Paweł Ochman
Agata Sackiewicz
Marek Dedecjus
Identification of the Optimal Cut-Off Value of PSA for Assessing Severity of Disease in [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT Study in Prostate Cancer Patients after Radical Prostatectomy
Diagnostics
positron emission tomography/computed tomography
prostate-specific membrane antigen
prostate cancer
title Identification of the Optimal Cut-Off Value of PSA for Assessing Severity of Disease in [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT Study in Prostate Cancer Patients after Radical Prostatectomy
title_full Identification of the Optimal Cut-Off Value of PSA for Assessing Severity of Disease in [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT Study in Prostate Cancer Patients after Radical Prostatectomy
title_fullStr Identification of the Optimal Cut-Off Value of PSA for Assessing Severity of Disease in [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT Study in Prostate Cancer Patients after Radical Prostatectomy
title_full_unstemmed Identification of the Optimal Cut-Off Value of PSA for Assessing Severity of Disease in [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT Study in Prostate Cancer Patients after Radical Prostatectomy
title_short Identification of the Optimal Cut-Off Value of PSA for Assessing Severity of Disease in [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT Study in Prostate Cancer Patients after Radical Prostatectomy
title_sort identification of the optimal cut off value of psa for assessing severity of disease in sup 68 sup ga ga psma 11 pet ct study in prostate cancer patients after radical prostatectomy
topic positron emission tomography/computed tomography
prostate-specific membrane antigen
prostate cancer
url https://www.mdpi.com/2075-4418/12/2/349
work_keys_str_mv AT paulinacegla identificationoftheoptimalcutoffvalueofpsaforassessingseverityofdiseaseinsup68supgagapsma11petctstudyinprostatecancerpatientsafterradicalprostatectomy
AT martawojewodzka identificationoftheoptimalcutoffvalueofpsaforassessingseverityofdiseaseinsup68supgagapsma11petctstudyinprostatecancerpatientsafterradicalprostatectomy
AT izabelagorczewska identificationoftheoptimalcutoffvalueofpsaforassessingseverityofdiseaseinsup68supgagapsma11petctstudyinprostatecancerpatientsafterradicalprostatectomy
AT wiolettachalewska identificationoftheoptimalcutoffvalueofpsaforassessingseverityofdiseaseinsup68supgagapsma11petctstudyinprostatecancerpatientsafterradicalprostatectomy
AT grazynałapinska identificationoftheoptimalcutoffvalueofpsaforassessingseverityofdiseaseinsup68supgagapsma11petctstudyinprostatecancerpatientsafterradicalprostatectomy
AT pawełochman identificationoftheoptimalcutoffvalueofpsaforassessingseverityofdiseaseinsup68supgagapsma11petctstudyinprostatecancerpatientsafterradicalprostatectomy
AT agatasackiewicz identificationoftheoptimalcutoffvalueofpsaforassessingseverityofdiseaseinsup68supgagapsma11petctstudyinprostatecancerpatientsafterradicalprostatectomy
AT marekdedecjus identificationoftheoptimalcutoffvalueofpsaforassessingseverityofdiseaseinsup68supgagapsma11petctstudyinprostatecancerpatientsafterradicalprostatectomy